NOVEL IMMUNOTHERAPEUTIC APPROACHES FOR THE PREVENTION OF VIRAL DISEASE IN IMMUNOCOMPROMISED SETTINGS

SWATHI MURALIDHAR 1,3, KIRSTEN SPANN 3, RAJIV KHANNA 2, COREY SMITH 3

1. Translational and Human Immunology, QIMR Berghofer; 2. Tumor Immunology, QIMR Berghofer; 3. Medical Biochemistry and Metabolomics, Department of Health, QUT, Kelvin Grove

BACKGROUND
- Epstein Barr virus (EBV) is a gammaherpesvirus associated with 90% global sero prevalence and lifelong latent infection.
- Primary infection is associated with Infectious Mononucleosis.
- Latent infections is associated with 200,000 cancers annually.
- Cancers in Immunocompetent patients: Lymphoma (HL, NK/T, DLBCL, BL); and Epithelial (NPC, GC).
- Epidemiological link to autoimmune diseases particularly Multiple Sclerosis.
- Currently no targeted antiviral/immunotherapeutics

RATIONALE
- Evaluation of NRG humanized mouse model – Virological and immunological parameters of EBV infection
- Cellular adoptive T cell therapy- prophylactic and therapeutic models in vivo
- Drug based immunotherapy

AIMS
- Evaluation of NRG humanized mouse model – Virological and immunological parameters of EBV infection
- Cellular adoptive T cell therapy- prophylactic and therapeutic models in vivo
- Drug based immunotherapy

METHODOLOGY

RESULTS AND CONCLUSIONS

ACKNOWLEDGEMENTS

Dr. Katie Lineburg (Post doc), Srividhya Beckett, Dr. Debamrita Sinha (Tumor Immunology Group), QIMR Berghofer.